Chronic active multiple sclerosis lesions, characterized by a hyperintense rim of iron-enriched, activated microglia and macrophages, have been linked to greater tissue damage. Post-mortem studies have determined that chronic active lesions are primarily related to the later stages of multiple sclerosis; however, the occurrence of these lesions, and their relationship to earlier disease stages may be greatly underestimated. Detection of chronic active lesions across the patient spectrum of multiple sclerosis requires a validated imaging tool to accurately identify lesions with persistent inflammation. Quantitative susceptibility mapping provides efficient in vivo quantification of susceptibility changes related to iron deposition and the potential to identify lesions harbouring iron-laden inflammatory cells. The PET tracer 11 C-PK11195 targets the translocator protein expressed by activated microglia and infiltrating macrophages. Accordingly, this study aimed to validate that lesions with a hyperintense rim on quantitative susceptibility mapping from both relapsing and progressive patients demonstrate a higher level of innate immune activation as measured on 11 C-PK11195 PET. Thirty patients were enrolled in this study, 24 patients had relapsing remitting multiple sclerosis, six had progressive multiple sclerosis, and all patients had concomitant MRI with a gradient echo sequence and PET with 11 C-PK11195.
Introduction
Multiple sclerosis is an inflammatory disease of the CNS, characterized by loss of myelin, leading to axonal damage and subsequent neurodegeneration. Both the adaptive and innate immune system play an important role in the pathophysiology of the disease, and contribute to focal inflammation and demyelination, leading to the formation of multiple sclerosis lesions (Marik et al., 2007; Kutzelnigg and Lassmann, 2014) . Multiple sclerosis lesions have been recently recategorized, and five distinct lesion patterns have been described (Frischer et al., 2015) . Amongst chronic lesions, the slowly expanding lesion or smouldering plaque has been identified as the lesion type contributing to ongoing demyelination. These chronic active lesions can be seen throughout the entire disease course, but have been mainly detected in patients with longstanding multiple sclerosis (Frischer et al., 2015) . Histopathologically, these chronic active lesions are characterized by a gliotic, hypocellular centre and a rim of activated microglia cells and macrophages (Marik et al., 2007; Hametner et al., 2013; Mehta et al., 2013; Dendrou et al., 2015; Grigoriadis and van Pesch, 2015) . Furthermore, the majority of the microglia and macrophages found at the rim of chronic active multiple sclerosis lesions contain iron (Hametner et al., 2013; DalBianco et al., 2017) , and conversely iron-enriched microglia and macrophages are not found at the rim of remyelinated or shadow plaques (Popescu et al., 2017) .
Current imaging techniques can detect accumulation of gadolinium in regions of acute lesion formation, indicating acute inflammation; however, no tool is available to visualize ongoing inflammation in chronic lesions, such as continuous microglial inflammation behind an intact blood-brain barrier. MRI with a gradient echo (GRE) sequence is sensitive to iron (Langkammer et al., 2010) and has been explored by many investigators to detect an iron rim in chronic active multiple sclerosis lesions (Hammond et al., 2008b; Bagnato et al., 2011; Mehta et al., 2013; Yao et al., 2015; Absinta et al., 2016; Dal-Bianco et al., 2017) . In a post-mortem study of predominantly progressive patients, Dal-Bianco et al. (2017) provided histopathological evidence that the presence of a phase rim within chronic lesions, which is derived from GRE data, is representative of iron-laden activated microglia and macrophages. Quantitative susceptibility mapping (QSM) provides an effective means to directly map the distribution of susceptibility sources by solving the field-tosource inversion problem using a phase-based magnetic field deconvolution technique , and allows the most accurate quantification and localization of brain iron as compared to other GRE approaches (Deistung et al., 2013; Langkammer et al., 2013) .
PET in combination with the ligand 11 C-PK11195 is used to evaluate activated microglia/macrophages in vivo (Boutin et al., 2015) . PK11195-PET binds to the 18 kDa translocator protein (TSPO), which is expressed on the outer mitochondria membrane of activated microglia/macrophages (Banati et al., 2000; Banati, 2002; Jucaite et al., 2012) . Studies with PK11195-PET have confirmed the most prominent uptake within areas of increased inflammation, especially in contrast-enhancing lesions, but has also demonstrated uptake within chronic multiple sclerosis lesions (Politis et al., 2012; Ratchford et al., 2012; Giannetti et al., 2015) , wherein cross-binding with reactive astrocytes has been demonstrated, suggesting that TSPO expression may be reflective of a diffuse glial inflammatory response (Cosenza-Nashat et al., 2009) . Although, PET provides a higher specificity as compared to MRI, limitations of spatial resolution may impact specific localization of molecular binding within smaller regions of interest (Vivash and O'Brien, 2016) .
Histologically, chronic active lesions have been found to be associated with longer disease duration and predominantly occur in progressive disease (Prineas et al., 2001; Frischer et al., 2015) with a peak occurrence at 50 years of age for both chronic active and shadow plaques. These observations suggest that the occurrence of chronic active lesions may serve as a transition point for relapsing to progressive disease (Frischer et al., 2015) . However, given the limited representation of younger, relapsing patients in post-mortem studies, the occurrence of chronic active multiple sclerosis lesions among younger patients remains speculative. Validation of QSM as a clinically feasible method to accurately identify chronic active multiple sclerosis lesions in younger, relapsing patient cohorts requires data beyond standard histopathological studies. An in vivo multi-modality imaging approach, utilizing both TSPO PET and QSM MRI, would provide an alternative strategy to confirm the presence of ongoing inflammation in chronic lesions identified among a diverse patient population.
The goal of our study was to provide imaging and histological evidence that QSM can identify chronic active multiple sclerosis lesions and that these lesions are found within the relapsing remitting phase of multiple sclerosis. We used PK11195-PET to measure innate immune activity in chronic multiple sclerosis lesions from a cohort consisting of both relapsing remitting and progressive patients, and determined if those lesions with a hyperintense rim on QSM have more inflammatory activity consistent with the classification of chronic active multiple sclerosis lesions. In a small set of imaged autopsy multiple sclerosis tissue, we investigated TSPO expression in lesions with a hyperintense rim (rim + ) as compared to those without (rimÀ), to confirm that TSPO expression co-localizes with inflammatory cells within the rim of the lesion, and to identify the proportion of microglia and astrocytes present within the TSPO cell population. The ultimate goal of this study was to utilize PK11195-PET as in vivo tool to provide evidence that QSM can identify lesions with persistent inflammation in both relapsing remitting and progressive multiple sclerosis, and may provide a clinically feasible in vivo tool to assess the heterogeneity of chronic lesions.
Materials and methods
Quantitative susceptibility measure versus PK11195-PET in multiple sclerosis patients Cohort This is a cross-sectional retrospective study, evaluating the uptake of PK11195 in chronic QSM rim + and QSM rimÀ lesions. Subjects eligible for the study were chosen based on the concomitant presence of PK11195 PET scan and MRI with QSM. Patients were selected from two ongoing and one concluded PK11195 studies, and all patients seen at the multiple sclerosis centre undergo MRI with QSM as part of a standard multiple sclerosis imaging protocol. All studies were approved by an ethical standards committee on human experimentation, and written informed consent was obtained from all patients. A cohort of 33 patients with relapsing remitting and secondary progressive multiple sclerosis were identified. Three patients were excluded since the interval between PK11195 PET scan and matching MRI exceeded 50 days. The remaining 30 patients were enrolled into the study, underwent PK11195 PET scans and MRIs with QSM, time between these scans was on average 9.97 days (range: 0-50 days, AE 13.6). Patient characteristics and clinical data were obtained within 1 month of the individual's brain MRI and PK11195-PET scan (Table 1) . The following clinical data were collected for all patients: gender, age, disease duration, Expanded Disability Status Score (EDSS), disease subtype, duration of treatment, days between PET scan and MRI, as well as most recent treatment. Presence of chronic lesions, number of rim + lesions, and gadolinium-enhancing lesions were also included.
MRI data acquisition and postprocessing
MRI was performed at 3 T using a GE Signa HDxt or Siemens Magnetom Skyra scanner within 50 days of the PET scans.
with and without gadolinium enhancement, T 2 -weighted (0.5 Â 0.5 Â 3 mm 3 ), and T 2 -FLAIR (1.2 Â 1.2 Â 1.2 mm 3 ) images were obtained.
Brain QSM maps with automatic uniform CSF zero reference (QSM0) (Liu et al., 2018; Yao et al., 2017) were reconstructed from multi-echo GRE data using the morphology-enabled dipole inversion (MEDI) method (de Rochefort et al., 2010; Liu et al., 2012) and incorporating automated segmentation and regularization specific to CSF. Briefly, CSF within the lateral ventricles was identified by thresholding of R2 * map (R2 * 5 5 s
À1
) and imposing voxel connectivity. A regularization term penalizing susceptibility variation within the CSF mask was incorporated into MEDI algorithm to search for a solution with homogeneous CSF susceptibility.
All MRI images were aligned onto FreeSurfer volume with the boundary-based registration and tissue segmentation. Lesion regions of interest were identified on T 2 -weighted and T 2 -FLAIR images using an in-house lesion segmentation program followed by manual edits if necessary. Enhancing lesions were excluded from analysis. Normal-appearing white matter masks were generated and used as a reference for the PET quantification.
QSM hyperintense rim + lesions were identified based on chronic T 2 lesion by two trained neuroradiologists and one neurologist, and in case of discrepancy an independent neurologist decided on the presence of a positive hyperintense QSM rim. The identified lesions were differentiated into rim + and rimÀ lesions. The individual QSM lesion regions of interest were created by overlapping the individual T 2 -weighted region of interest onto the co-registered QSM images and further edited if necessary to better match the lesion geometry on QSM. The QSM value of the core was calculated by subtracting the QSM value of the rim from the lesion as a whole. For lesions without visible QSM signal, the original T 2 -weighted region of interest was utilized as the QSM lesion region of interest. Central veins were manually excluded from all lesions. QSM values were extracted based on the corrected lesion. To further refine our population of QSM rim + lesions, only lesions with an average susceptibility value above 0 (the reference susceptibility of CSF) within the rim remained characterized as rim + lesions.
PK11195 radioligand production and PET imaging
The radioligand [N-methyl-11C(R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide], known as 11 C-PK11195 was prepared by modifying previously described procedures. Briefly, 1 mg (2.95 mol) desmethyl-PK11195 in 350 ml DMSO was treated with 10 mmol aqueous sodium hydroxide and allowed to react with (C-11) methyl iodide. Following reaction 11 C-PK11195 was purified by high performance liquid chromatography and formulated in saline with 7% ethanol. Following intravenous administration of 370-555 MBq (10-15 mCi) of 11 C-PK11195, dynamic PET scans over a period of 60 min were acquired in list mode with a whole-body PET/ CT scanner (mCT, Siemens/CTI). The PET camera has a spatial resolution of $4 mm measured as the reconstructed full-width at half-maximum of a point source in air. PET scans were corrected for photon absorption and scatter, using an in-line CT scanner set at 120 kV, a pitch of 1.5, and 30 mA. PET data were reconstructed in a 400 Â 400 matrix with a voxel size of 1.082 Â 1.082 Â 2.025 mm 3 using a zoom of 2.0 and an iterative + time of flight (TOF) list-mode reconstruction algorithm provided by the manufacturer.
PET data analysis
PET images were reconstructed into 22 frames (four frames of 15 s each, then 4 Â 30 s, 3 Â 60 s, 2 Â 120 s, 8 Â 300 s and 1 Â 600 s). For the image-derived input function (IDIF), circular region of interest measuring 4 mm in diameter were placed manually in the C4 area of the carotid artery on summed transaxial PET images acquired between 90-120 s after the start of the 60 s infusion. These regions of interest were then automatically transposed onto the other frames without further operator input. Summed PET images were co-registered to their corresponding MRI scans using PMOD Õ (PMOD Technologies Ltd) (Mikolajczyk et al., 1998) . The T 2 -based regions of interest, representing individual lesions, were co-registered with the PET images to interrogate individual chronic lesions. PK11195 uptake was analysed for both rim + and rimÀ lesions to evaluate if the presence of iron in the rim of rim + lesions corresponds to microglia activity depicted on PK11195-PET.
PET quantification and image-derived input function
For the estimation of PK volume of distribution (VT), the concentration of radioactivity in brain and whole blood was applied to the Logan graphical method (Logan et al., 1990) . Population metabolite data were used to provide correction for the input function (Roivainen et al., 2009) . Image and kinetic analyses were performed using PMOD 3.5. VT ratio (VTr), defined as the ratio of VT within a specific lesion and that within an individual's normal-appearing white matter, was calculated to control for normal physiological variability, which is known to influence absolute VT measurement (Hammoud et al., 2005) . Normal-appearing white matter was selected as a reference to have a matching tissue compartment to the white matter lesions analysed for this study (Kaunzner et al., 2017 fixed brain tissue was obtained from seven subjects with multiple sclerosis (Supplementary Table 1 ).
MRI data acquisition and post-processing
Post-mortem brain slabs were imaged at 3 T using T 2 -FLAIR sequence (0.8 Â 0.8 Â 0.6 mm 3 ) for anatomy and 3D multiecho GRE sequence [0.6 Â 0.6 Â 0.6 mm 3 , echo time (TE)1 = 4.3 ms, ÁTE = 4.8 ms, number of TEs = 11, three orientations] for multiple orientation reconstruction of QSM (COSMOS) (Liu et al., 2009) . Multiple sclerosis lesions were categorized into rim + and rimÀ lesions based on either high or isointense susceptibility on QSM at the lesion rim.
Immunohistochemistry
Following MRI, the formalin-fixed brain tissue was cut in areas of interest, embedded in paraffin and blocks were sectioned at 5 mm thickness. After quenching with 0.03% hydrogen peroxide and blocking with normal serum, sections were incubated with primary antibodies (antibodies against CD68s and TSPO) overnight (Supplementary Table 2 ), processed with the appropriate biotinylated secondary antibody and avidin/biotin staining kit with 3,3 0 -diaminobenzidene (DAB) as the chromogen (Vector ABC Elite Kit and DAB Kit, Vector Laboratories), and counterstained with haematoxylin. Adequate controls using isotype control antibodies were performed for each primary antibody. Iron was detected with DAB-enhanced Perls' staining (Prussian blue reaction). For this, slides were immersed in 4% ferrocyanide/4% hydrochloric acid for 30 min in the dark. Iron staining was enhanced through incubation with DAB for 30 min at room temperature (Mehta et al., 2013) , and sections were counterstained with neutral red (Vector Laboratories). Sections were rinsed with distilled water, dehydrated, and cover-slipped with Permount (Vector Laboratories). Brightfield images were acquired with a Leica DM5000 B microscope using a Leica colour camera DFC310 Fx and the Leica Application Suite (version 4.9.0) imaging software. Images were processed with Panoramic Viewer (3DHISTECH) and Photoshop (Adobe) software.
Fluorescent immunohistochemistry
For fluorescence immunohistochemistry, sections were blocked with Fc receptor binding inhibitor followed by normal serum, incubated with primary antibodies (Supplementary Table 2) overnight at 4 C, and processed with the appropriate fluorophore-conjugated secondary antibodies (Supplementary  Table 3 ). Subsequently, sections were dyed with 0.3% Sudan Black to quench auto-fluorescence and cover-slipped with Vectashield HardSet Antifade Mounting Medium (Vector Laboratories). Sections were examined and images acquired on an UltraVIEW VoX (Perkin Elmer) spinning disc confocal Nikon Ti-E Eclipse microscope using the Volocity 6.3 software (Improvision). Images were processed with ImageJ software (Schneider et al., 2012) . At the rims of two iron + and one ironÀ chronic active lesions, we quantified the number of TSPO + cells that were GFAP + , CD68 + or neither. Average TSPO expression per cell was quantified by densitometric analysis of fluorescent immunoreactivity. Acquisition and analysis were performed in a blinded manner.
Statistical analysis
Mean QSM rim + and rimÀ susceptibility and VTr differences were compared with a two-sided t-test. The mean QSM values within the lesion core and rim areas of rim + lesions were compared by paired t-test.
Regression models were implemented with QSM and VTr at the lesion level as response variables. Covariates of interest included patient age, gender, individual T 2 -weighted lesion volume, disease subtype (relapsing remitting versus progressive), patient having an enhancing lesion (yes/no) and treatment duration. Two mixed-effects regression models were implemented to measure the association between the covariates above and each response variable while controlling for rim + and rimÀ lesions. Our model strategy also accounts for multiple lesions per patient. The final model was found using a back-fitting procedure set at alpha = 0.10 for inclusion. The analysis was performed using R (R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; URL http://www.R-project.org/).
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Results

Patient characteristics
This was a cross-sectional study combining QSM-MRI with PK11195 PET imaging. The cohort of 30 patients is described in Table 1 , including 18 females and 12 males, aged 43.8 AE 14.3 years, with disease duration 13.1 AE 11.9 years and EDSS = 2.5 AE 2.3. Twenty-four patients carried a diagnosis of relapsing remitting multiple sclerosis and six patients had secondary progressive multiple sclerosis. All patients except four were on disease-modifying treatment when the scans were obtained. Two patients had contrast enhancing lesions on MRI.
Susceptibility values in lesions
A total of 406 chronic lesions were identified based on T 2 -weighted images, 43 (43/406 = 11%) were rim + , and 363 (89%) were rimÀ. Forty-five rim + lesions were visually identified, and after applying the second identification step, selecting only rim + lesions based on positive rim QSM values, two lesions were excluded, and 43 rim + lesions remained in the analysis. Six enhancing lesions were detected and had an average QSM of À23.76 ppb ( AE16.73 ppb); these lesions were excluded from the analysis. The distribution of QSM rim + lesions was found to be similar to that of rimÀ lesions within the brain ( Supplementary  Fig. 1 ). Figure 1 exemplifies these two types of chronic multiple sclerosis lesions on T 2 -weighted ( Fig. 1A and C) , one being rim + (Fig. 1B) the other rimÀ (Fig. 1D) . Two (2/6 = 33%) progressive patients had a total of five rim + lesions, the remaining 38 lesions were found in patients with relapsing remitting multiple sclerosis. Mean QSM volume was 676.1 AE 472.1 mm 3 for rim + lesions and 303.8 AE 430.7 mm 3 for rimÀ lesions. Mean whole lesion susceptibility was higher in rim + (2.42 ppb AE17.45) compared to rimÀ lesions (À14.6 ppb AE 19.3, P 5 0.0001). In the final model accounting for patient variability as random effect (mixed effects model), age remained as a significant covariate (b = À0.358, P = 0.048) and susceptibility values in rim + lesions remained significantly higher than in rimÀ lesions, P 5 0.006. In rim + lesions, the volumes of rim and core area were 218.4 AE 223.0 mm 3 and 457.7 AE 397.6 mm 3 , respectively. The mean susceptibility within the rim (20.04 ppb AE 14.28) was significantly higher compared to the core (À5.49 ppb AE 14.44, P 5 0.0001).
PK11195 uptake in lesions
PK11195 uptake was higher in rim + (VTr = 1.01 AE 0.16) for rim + as compared to rimÀ (VTr = 0.93 AE 0.12) lesions ( Fig. 2A) . This difference became more evident in the mixed-effect model, which showed that whole-lesion VTr values were 0.052 units higher for rim + lesions as compared to rimÀ lesions (P = 0.015) (Fig. 2B ). Lesion volume (individual lesions) remained as a significant covariate (b = À0.0003091, P 5 0.001) in the model and due to the interaction found with patient age (interaction variable P 5 0.001), the final model included both lesion volume and patient age. Figure 3 demonstrates the signal uptake differences of rim + and rimÀ lesions that were observed on PK11195-PET.
Presence of TSPO on immunohistochemistry
Immunohistochemical validation of TSPO signal was performed on formalin fixed brain tissue derived from seven multiple sclerosis patients, to confirm that the PK11195-PET uptake in QSM rim + lesions is related to a dense inflammatory response within the rim. Lesion types were distinguished into rim + and rimÀ lesion, based on the presence of a QSM rim on MRI ( Fig. 4A and E) , which was confirmed with immunohistochemistry for iron, using Perls' staining (Fig. 4) . A total of three rim + and four rimÀ lesions were processed for this analysis. The upper panel of Fig. 4A and B) . As expected, iron was present in CD68 + myeloid cells ( Fig. 4B and C) . A multitude of strongly stained TSPO + cells were found throughout the expansive hyperintense rims of iron positive lesions. These cells were determined by morphology to be microglia, macrophages or astrocytes (Fig. 4D) . In rimÀ lesions, iron-positive cells were not present at the lesion border (Fig. 4F) and only a few CD68 + microglial cells were seen (Fig. 4G) . The smaller number of inflammatory cells at the lesion border of rimÀ lesions also expressed TSPO (Fig. 4H) . This immunohistochemistry pattern was demonstrated among the set of three rim + and four rimÀ lesions. These findings demonstrate a wide rim of iron-related inflammation in QSM rim + lesions, which relates to a proportional increase of TSPO + cells and is congruent with our in vivo imaging results.
Fluorescent immunohistochemistry was also obtained to assess the distribution of CD68 + microglia cells (Fig. 5D ) as well as GFAP + astrocytes (Fig. 5C) within the TSPO + cell population (Fig. 5B) . Within TSPO + cells a higher proportion of microglia cells was observed, as compared to TSPO + astrocytes ( Fig. 5A and G) . Average TSPO expression within GFAP + and CD68 + cells was quantified using densitometry (Fig. 5H ).
Discussion
In this study, we applied a multi-modality approach to explore chronic active multiple sclerosis lesions, with the goal to utilize an in vivo tool to visualize persistent innate immune activity in chronic lesions among both relapsing remitting and progressive multiple sclerosis patients.
We detected a significantly higher susceptibility in rim + lesions as compared to rimÀ lesions, and as expected, we found higher susceptibility in the rim of rim + lesions, in contrast to the core of these lesions. This result was supported by the known histopathological description of iron in the border of chronic active multiple sclerosis lesion (Hametner et al., 2013) . Aside from histopathology, known radiological findings show the presence of a paramagnetic, iron-positive rim, using T 2 * -weighted and phase imaging (Hammond et al., 2008a; Pitt et al., 2010; Absinta et al., 2013) ; however, these techniques do not allow a quantitative analysis. QSM has been introduced more recently as an elegant postprocessing method, using a magnetic field deconvolution technique to further refine susceptibility imaging. It recovers susceptibility from the phase distribution, and overcomes problems encountered with other GRE approaches, like the field-to-source inversion problem and occurrence of blooming artefacts. Thus, QSM has been established as a more sensitive and quantitative technique for measuring brain iron as compared to T 2 * , R2 and R2 * (Deistung et al., 2013; Langkammer et al., 2013) . Our group previously described that tissue magnetic susceptibility, as measured by QSM, is highly dynamic in multiple sclerosis lesions. Susceptibility increases rapidly as acute lesions transition from enhancing to non-enhancing and dissipates gradually back to that of surrounding white matter, over a span of several years (Chen et al., 2014; Zhang et al., 2016) . It has been well established that iron and myelin are the main contributors of magnetic susceptibility in white matter. While iron is a paramagnetic material with positive susceptibility with respect to water, myelin is diamagnetic and has negative susceptibility (Wisnieff et al., 2015) . Accordingly, the susceptibility of a fully demyelinated lesion without any iron accumulation should be at most zero (the reference susceptibility of CSF water in this study), and lesion susceptibility above zero on QSM provides an unequivocal indication of iron (Liu et al., 2018) . This positive QSM criterion was used to identify rim + lesion to assure that only lesions with true iron deposition would be included in the analysis.
Microglia comprise a heterogeneous population of CNS residential, antigen presenting cells that are able to exhibit pro-and anti-inflammatory features. In multiple sclerosis, the pro-inflammatory microglia type induces mitochondrial changes, and oxidative stress through the secretion of reactive oxygen species, contributing to demyelination and neuronal destruction (Prineas et al., 2001) . Histopathology of chronic active lesions demonstrates activated microglia in the border of this lesion type (Frischer et al., 2015) , and iron has been detected in activated microglia within the lesion rim (Hametner et al., 2013) . It has been well described that CD68-positive microglia and macrophages exhibit various inflammatory markers, and the presence of intracellular iron has been associated with polarization of microglia and macrophages towards a pro-inflammatory state (Mehta et al., 2013) . Iron in activated, pro-inflammatory microglia thought to be derived from myelin and oligodendrocyte debris, as part of the demyelinating process (Bagnato et al., 2011; Hametner et al., 2013 ). An alternative hypothesis is that iron is released by oligodendrocytes in white matter adjacent to plaques, a process that is thought to be induced by inflammatory cytokines, excreted by microglia (Zhang et al., 2005; Popescu et al., 2017) .
Aside from histopathology, different imaging modalities have been applied and various studies have been conducted to explore the presence of innate immune cells in patients with multiple sclerosis in vivo. PET imaging, in combination with first and second generation TSPO ligands, has been used to explore this activated microglia in normalappearing white matter, active and chronic multiple sclerosis lesions, and has been used to monitor response to individual disease-modifying treatments (Banati et al., 2000; Debruyne et al., 2003; Politis et al., 2012; Ratchford et al., 2012; Kaunzner et al., 2017; Sucksdorff et al., 2017) . We used Logan-VT calculated with image derived input function, which has been demonstrated as a feasible alternative to arterial sampling for PK11195 quantification in multiple sclerosis lesions (Kaunzner et al., 2017) . Merging two imaging methods, PK11195-PET and QSM, we here demonstrated that uptake of PK11195 was significantly higher in rim + lesions, proving a higher level of inflammation within this lesion type. These results were consistent with our recent work demonstrating that multiple sclerosis lesions with QSM rim are associated with more tissue injury, as measured by myelin water imaging; both observations were consistent with the identification of chronic active multiple sclerosis lesions (Yao et al., 2017 ). This conclusion is further supported by additional GRE studies demonstrating that phase rim lesions are consistent with chronic active lesions, and are more likely to develop into a chronic T 1 -weighted hypointense lesion (Absinta et al., 2016) and demonstrate slow expansion (Dal-Bianco et al., 2017) .
The rationale for the immunohistochemical aspect of this study is based on the poor spatial resolution of PK11195-PET and inability to delineate inflammatory activity within the rim as compared to the core of a chronic lesion. Given this limitation, we wanted to ensure that the increased TSPO signal within QSM rim + lesion was derived from an inflammatory response at the rim of these lesions. The histopathological correlates of our study showed a broad rim of iron containing CD68 + cells within QSM rim + lesions co-localizing with extensive TSPO + staining and a proportionally smaller TSPO expression was associated with a thin layer of iron-negative CD68 + microglia in rimÀ lesions. Importantly, on fluorescent immunohistochemistry, we found that proportionally more TSPO + microglia cells were found across both lesion types as compared to TSPO + astrocytes. This supports the conclusion that an increased TSPO signal among multiple sclerosis lesions is predominantly related to activated microglia/ macrophages and to a lesser extent due to astrocytes. These results and previous in vitro experiments demonstrating preferential iron uptake by M1 (pro-inflammatory) rather than M2 (anti-inflammatory) polarized macrophages provide evidence that QSM could be more selective for detecting lesions containing a subset of iron-laden pro-inflammatory cells (Mehta et al., 2013) . Further studies are required to investigate if iron-laden microglia and macrophages have more pro-inflammatory capability, and support QSM as a tool to identify lesions with high proinflammatory activity and potential for ongoing damage.
Histopathology studies have provided our current understanding of chronic active lesions and established the concept that these lesions are predominantly seen in patients with longstanding disease or progressive multiple sclerosis (Popescu et al., 2013; Frischer et al., 2015; Reich et al., 2018) . In this context, the hypothesis has been raised that the adaptive immunity-driven process may switch to a predominantly innate immune reaction during transition from relapsing remitting multiple sclerosis to secondary progressive disease. However, given the nature of autopsy studies, specifically as it relates to the represented population and disease states, there is lack of knowledge regarding the existence of chronic active lesions within the full spectrum of the disease. In our study QSM rim + lesions were observed in both relapsing remitting and progressive multiple sclerosis patients, and only two out of six progressive patients had chronic active lesions. In a previous in vivo QSM study of 24 multiple sclerosis patients, the presence of a rim on QSM was predominantly found among the three progressive patients (Harrison et al., 2016) , which is clearly contradictory to our results but congruent with postmortem observations. The difference in the aforementioned study and our work is unclear, but a larger cohort of patients, including patients with relapsing remitting and progressive multiple sclerosis is required to study the presence of chronic active lesions within the different disease subtypes. QSM could be used for this type of study, since it offers an ideal means to differentiate and monitor lesion subtypes across the spectrum of the disease, and can provide data that otherwise would not be obtained through post-mortem studies.
There are limitations to our study. We used TSPO marker PK11195, which, as mentioned, can also detect reactive astrocytes and limits its utility to confirm the cellular specificity of our QSM signal. However, our immunohistochemistry results demonstrated that the TSPO + signal co-localized with inflammatory cells (comprised of predominantly CD68 + microglia) at the rim of the lesion and was proportionally higher in rim + lesions. These combined results provide further evidence that inflammation measured by PK11195-PET was likely derived from cells expressing TSPO at the rim of the lesion. Furthermore, it remains unknown if second or third generation TSPO ligands could provide a higher level of spatial resolution to delineate inflammation localized to the rim. In addition, the newer generation TSPO ligands are disadvantaged by the genetic variability in binding affinity and quantification methods that remain under investigation. Lastly, our cohort size is quite small and a larger cohort, including clinically isolated syndrome, relapsing remitting and progressive patients is warranted to further explore the detection of QSM rim + lesions.
To our knowledge, this is the first study to use a multimodality imaging approach to provide in vivo evidence, using PK11195-PET, that chronic lesions with a hyperintense rim on QSM represent lesions with persistent inflammation. The benefit of PET imaging is that it offers an established and sensitive tool to detect chronic inflammation in vivo. Nonetheless, it carries the disadvantage of radiation and poor spatial resolution as well as being a time-consuming and costly imaging tool that cannot be easily applied in routine clinical practice. However, QSM can be rapidly and reliably acquired with standard field strength (3 T) MRI scanners (Deh et al., 2015) ; and therefore can be easily implemented in clinical settings. Differentiating chronic multiple sclerosis lesion subtypes, especially chronic active lesions and recognizing ongoing biological activity, such as a high degree of inflammation, would provide a unique biomarker for disease activity and a potential treatment target for both relapsing remitting and progressive patients. This might be particularly important for the evaluation of efficacy of medications with CNS penetration (Goyal et al., 2014) , and the potential for a direct effect on CNS immune modulation (Draheim et al., 2016) . Compounds and medications that have shown these features in preclinical studies are siponimod (O'Sullivan et al., 2016) and the combination of minocycline/hydroxychloroquine (Faissner et al., 2017) , as well as currently approved treatments such as dimethyl fumerate (Wilms et al., 2010; Linker et al., 2011; Gillard et al., 2015; Parodi et al., 2015; Peng et al., 2016; Schulze-Topphoff et al., 2016; Diebold et al., 2017) and fingolimod (Colombo et al., 2014; O'Sullivan et al., 2017) .
In conclusion, we present data that QSM can target chronic inflammatory lesions, consistent with the identification of chronic active multiple sclerosis lesions. Building on our work, larger clinical studies can be designed to establish the role of QSM rim + lesions as a predictive biomarker for disease activity and identify patients at risk for future disability.
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